Publications

In this section you will find a list of scientific publications relevant to the IBD community and in which EFCCA has been the co-author.

The Lucid Study

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe December, 2021 Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients. The aim of this study was to determine the socioeconomic burden of UC in adult patients in...

Correction to: The LUCID study

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe December, 2021 After publication of the LUCID study, the authors reported that the author name “Avedano” was incorrectly written as “Avendano”. The original article has been updated. Read Study 

The impact of perianal fistula in Crohn’s disease on quality of life

The impact of perianal fistula in Crohn’s disease on quality of life: results of a patient survey conducted in Europe May, 2021 Perianal fistulas (PAF) in Crohn’s disease (CD) may impair social performance, sexual function, life activities and overall patients’ quality of life (QoL). Patient experience is important in the treatment decision making and in providing adequate support. Despite...

Conjugal inflammatory bowel disease

Conjugal inflammatory bowel disease: a systematic review and European survey February, 2021 The frequency of inflammatory bowel disease (IBD) is increased after marriage to an individual with the disease. Importantly, the offspring of these couples have a significant risk for developing the disease. Herein, the study  aimed to better characterise conjugal IBD. Read Study 

Patients’ perceptions of surgery for IBD

Patients’ perceptions of surgery for inflammatory bowel disease August, 2020 Surgery is indicated in selected patients with inflammatory bowel disease (IBD). However, due to a negative perception, surgery may be delayed, leading to possible unfavourable outcomes. The aim of this work was to investigate patients’ perceptions of surgery and the impact on reported outcomes. Read study...

Patients' perspectives on smoking and inflammatory bowel disease

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations August, 2020 Smoking has detrimental effects on Crohn’s disease (CD) activity while data on ulcerative colitis (UC) are conflicting. Little is known about the use and impact of alternative smoking products in inflammatory...

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients August, 2020 In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients. Read Study    

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Patients with chronic diseases have experienced substantial changes to the routine management of their conditions during the coronavirus disease 2019 (COVID-19) pandemic.1,2 Although insights into the management of patients with inflammatory bowel disease (IBD) during the outbreak have been described,3...

Quality of Care Standards in Inflammatory Bowel Diseases

Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper February, 2020 The management of inflammatory bowel disease [IBD] is complex, and requires tight control of disease activity, close monitoring to avoid treatment side effects, health care professionals with expertise in IBD, and an interdisciplinary, holistic approach...

The Future of Biosimilars

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases February, 2020 Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can...